Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Name: Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Published: 2026
License: Public Domain

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

carcinoma immunotherapy liver-cancer

biliary tract cancers, intrahepatic cholangiocarcinoma (icc), extrahepatic cholangiocarcinoma, gallbladder carcinoma, ampulla of vater carcinoma, ampullary carcinoma, daraxonrasib (rmc-6236), kras (kirsten rat sarcoma virus) mutations, immunotherapy, biliary tract cancer, liver cancer, carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 812472
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.